电邮这篇文章 Current treatment of chronic lymphocytic leukemia. New opportunities and new difficulties
- 作者: Samoylova OS1
-
隶属关系:
- N.A.Semashko Nizhny Novgorod Regional Clinical Hospital
- 期: 卷 18, 编号 5 (2016)
- 页面: 16-19
- 栏目: Articles
- URL: https://medbiosci.ru/1815-1434/article/view/27104
- ID: 27104
如何引用文章
详细
Chronic lymphocytic leukemia (CLL) - the most common subtype of hemoblastoses (22-30%). It can have aggressive or indolent course, with diverse clinical symptoms. The foundation of this diversity is the molecular features of the disease. The incidence of CLL in Russia is 6.67 per 100 000 population. By 2016 several novel therapies for CLL have been registered in Russia, including ibrutinib and obinutuzumab, but the implementation of the novel drugs into daily practice meets certain difficulties. This article describes some of them based on the experience on the N.A.Semashko Nizhny Novgorod regional clinical hospital.
作者简介
O Samoylova
N.A.Semashko Nizhny Novgorod Regional Clinical Hospital
Email: samoilova_home@mail.ru
канд. мед. наук, зав. гематологическим отд-нием терапевтической клиники ГБУЗ НОКБ им. Н.А.Семашко, гл. гематолог Приволжского федерального округа 603126, Russian Federation, Nizhny Novgorod, ul. Rodionova, d. 190
补充文件
